Savara (NASDAQ:SVRA) Trading Down 8.4% – Should You Sell?

Savara Inc (NASDAQ:SVRA) shares traded down 8.4% during trading on Friday . The stock traded as low as $2.95 and last traded at $2.95. 1,088,001 shares traded hands during mid-day trading, an increase of 14% from the average session volume of 952,360 shares. The stock had previously closed at $3.22.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Savara in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.83.

Savara Price Performance

The stock’s fifty day moving average is $2.90 and its 200-day moving average is $3.04. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a market capitalization of $494.06 million, a P/E ratio of -6.65 and a beta of 0.44.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.27 million for the quarter. On average, equities analysts anticipate that Savara Inc will post -0.45 earnings per share for the current year.

Institutional Trading of Savara

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SVRA. Cibc World Markets Corp bought a new position in shares of Savara during the 4th quarter worth about $33,000. XTX Topco Ltd bought a new position in Savara during the fourth quarter valued at about $34,000. Ameriprise Financial Inc. acquired a new position in Savara in the 4th quarter valued at approximately $37,000. KLP Kapitalforvaltning AS bought a new stake in shares of Savara in the 4th quarter worth approximately $41,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Savara during the 4th quarter worth approximately $48,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.